209 related articles for article (PubMed ID: 35060346)
1. Local consolidative therapy for synchronous oligometastatic non-small cell lung cancer treated with first-line pembrolizumab: A retrospective observational study.
Chen Y; Wang Y; Yang Z; Hu M; Lu J; Zhang Y; Qian F; Zhang B; Wang S; Wang K; Zhang W; Han B
Thorac Cancer; 2022 Mar; 13(5):732-741. PubMed ID: 35060346
[TBL] [Abstract][Full Text] [Related]
2. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs.
Xu Q; Zhou F; Liu H; Jiang T; Li X; Xu Y; Zhou C
J Thorac Oncol; 2018 Sep; 13(9):1383-1392. PubMed ID: 29852232
[TBL] [Abstract][Full Text] [Related]
3. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.
Gomez DR; Tang C; Zhang J; Blumenschein GR; Hernandez M; Lee JJ; Ye R; Palma DA; Louie AV; Camidge DR; Doebele RC; Skoulidis F; Gaspar LE; Welsh JW; Gibbons DL; Karam JA; Kavanagh BD; Tsao AS; Sepesi B; Swisher SG; Heymach JV
J Clin Oncol; 2019 Jun; 37(18):1558-1565. PubMed ID: 31067138
[TBL] [Abstract][Full Text] [Related]
4. Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment.
Ni Y; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
J Cancer Res Clin Oncol; 2020 Jan; 146(1):197-203. PubMed ID: 31599340
[TBL] [Abstract][Full Text] [Related]
5. Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC).
Elamin YY; Gomez DR; Antonoff MB; Robichaux JP; Tran H; Shorter MK; Bohac JM; Negrao MV; Le X; Rinsurogkawong W; Lewis J; Lacerda L; Roarty EB; Swisher SG; Roth JA; Zhang J; Papadimitrakopoulou V; Heymach JV
Clin Lung Cancer; 2019 Jan; 20(1):43-47. PubMed ID: 30343004
[TBL] [Abstract][Full Text] [Related]
6. Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small-Cell Lung Cancer.
Mitchell KG; Farooqi A; Ludmir EB; Corsini EM; Zhang J; Sepesi B; Vaporciyan AA; Swisher SG; Heymach JV; Zhang J; Gomez DR; Antonoff MB
Clin Lung Cancer; 2020 Jan; 21(1):37-46.e7. PubMed ID: 31447303
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L).
Miyawaki T; Kenmotsu H; Harada H; Ohde Y; Chiba Y; Haratani K; Okimoto T; Sakamoto T; Wakuda K; Ito K; Uemura T; Sakata S; Kogure Y; Nishimura Y; Nakagawa K; Yamamoto N
BMC Cancer; 2021 Oct; 21(1):1121. PubMed ID: 34663250
[TBL] [Abstract][Full Text] [Related]
8. Local Ablative Therapy Combined with Pembrolizumab in Patients with Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Recursive Partitioning Analysis.
Lee HI; Choi EK; Kim SS; Shin YS; Park J; Choi CM; Yoon S; Kim HR; Cho YH; Song SY
Int J Radiat Oncol Biol Phys; 2024 May; ():. PubMed ID: 38797499
[TBL] [Abstract][Full Text] [Related]
9. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations.
Hu F; Xu J; Zhang B; Li C; Nie W; Gu P; Hu P; Wang H; Zhang Y; Shen Y; Wang S; Zhang X
Clin Lung Cancer; 2019 Jan; 20(1):e81-e90. PubMed ID: 30341018
[TBL] [Abstract][Full Text] [Related]
11. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
Buti S; Bersanelli M; Perrone F; Bracarda S; Di Maio M; Giusti R; Nigro O; Cortinovis DL; Aerts JGJV; Guaitoli G; Barbieri F; Ferrara MG; Bria E; Grossi F; Bareggi C; Berardi R; Torniai M; Cantini L; Sforza V; Genova C; Chiari R; Rocco D; Della Gravara L; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Citarella F; Russano M; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Follador A; Bisonni R; Tuzi A; Minuti G; Landi L; Ricciardi S; Migliorino MR; Tabbò F; Olmetto E; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Addeo A; Friedlaender A; Cannita K; Porzio G; Ficorella C; Carmisciano L; Pinato DJ; Mazzaschi G; Tiseo M; Cortellini A
Eur J Cancer; 2021 Jun; 150():224-231. PubMed ID: 33934059
[TBL] [Abstract][Full Text] [Related]
12. Increased biologically effective dose (BED) to the primary tumor is associated with improved survival in patients with oligometastatic NSCLC.
Farooqi A; Ludmir EB; Mitchell KG; Antonoff MB; Tang C; Lee P; Chang J; Elamin Y; Gomez DR; Gandhi SJ
Radiother Oncol; 2021 Oct; 163():114-118. PubMed ID: 34419505
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179.
Anouti B; Althouse S; Durm G; Hanna N
Clin Lung Cancer; 2020 May; 21(3):288-293. PubMed ID: 32143966
[TBL] [Abstract][Full Text] [Related]
14. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.
Borghaei H; Langer CJ; Gadgeel S; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Saraf S; Keller SM; Gandhi L
J Thorac Oncol; 2019 Jan; 14(1):124-129. PubMed ID: 30138764
[TBL] [Abstract][Full Text] [Related]
15. Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals
De B; Farooqi AS; Mitchell KG; Ludmir EB; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee JJ; Swisher SG; Gibbons DL; Zhang J; Le X; Elamin YY; Gomez DR; Ning MS; Lin SH; Liao Z; Chang JY; Vaporciyan AA; Heymach JV; Antonoff MB; Gandhi SJ
JCO Precis Oncol; 2023 Jan; 7():e2200540. PubMed ID: 36716413
[TBL] [Abstract][Full Text] [Related]
16. Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
Cortellini A; Cannita K; Tiseo M; Cortinovis DL; Aerts JGJV; Baldessari C; Giusti R; Ferrara MG; D'Argento E; Grossi F; Guida A; Berardi R; Morabito A; Genova C; Antonuzzo L; Mazzoni F; De Toma A; Signorelli D; Gelibter A; Targato G; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Mansueto G; Zoratto F; Filetti M; Bracarda S; Citarella F; Russano M; Cantini L; Nigro O; Buti S; Minuti G; Landi L; Ricciardi S; Migliorino MR; Natalizio S; Simona C; De Filippis M; Metro G; Adamo V; Russo A; Spinelli GP; Di Maio M; Banna GL; Friedlaender A; Addeo A; Pinato DJ; Ficorella C; Porzio G
Eur J Cancer; 2021 May; 148():24-35. PubMed ID: 33721704
[TBL] [Abstract][Full Text] [Related]
17. Local Consolidative Therapy Versus Systemic Therapy Alone for Metastatic Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Wu Y; Verma V; Liang F; Lin Q; Zhou Z; Wang Z; Wang Y; Wang J; Chang JY
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):635-644. PubMed ID: 35196537
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non-small-cell lung cancer: A multicenter retrospective trial.
Matsumoto H; Kobayashi N; Somekawa K; Fukuda N; Kaneko A; Kamimaki C; Kubo S; Tanaka K; Tagami Y; Teranishi S; Watanabe K; Horita N; Hara Y; Yamamoto M; Kudo M; Koizumi H; Miura K; Miyazawa N; Kaneko T
Thorac Cancer; 2022 Jan; 13(2):228-235. PubMed ID: 34866339
[TBL] [Abstract][Full Text] [Related]
19. Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients.
Hu F; Li C; Xu J; Guo J; Shen Y; Nie W; Zheng X; Wang L; Zhang H; Han B; Zhang X
Lung Cancer; 2019 Sep; 135():138-144. PubMed ID: 31446986
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
